Clinical trial NCT02693535: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Official title: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors
Keywords: cancer
off-label
precision medicine
targeted therapy
Lead sponsor: American Society of Clinical Oncology
Sponsor class: OTHER
Collaborators: name: AstraZeneca
name: Bayer
name: Bristol-Myers Squibb
name: Eli Lilly and Company
name: Genentech, Inc.
name: Merck Sharp & Dohme LLC
name: Pfizer
name: Boehringer Ingelheim
name: Seagen Inc.
name: Taiho Oncology, Inc.
First posted: 2016-02-26
Enrollment: 4200
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Detailed description: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Eligibility criteria: Inclusion Criteria:

* 12 years of age or older (\*Restrictions apply. Not all therapies are available for patients \<18)
* Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
* Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
* Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:

  1. Absolute neutrophil count ≥ 1.5 x 106/µl
  2. Hemoglobin \> 9.0 g/dl
  3. Platelets \> 75,000/µl
  4. Total bilirubin \< 2.0 mg/ dl, except in patients with Gilbert's Syndrome
  5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) \< 2.5 x institutional upper limit of normal (ULN) (or \< 5 x ULN in patients with known hepatic metastases)
  6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
* Patients must have disease that can be objectively measured by physical or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible.
* Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
* Ability to understand and the willingness to sign a written informed consent/assent document.
* Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
* For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
* Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse.

Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.

Exclusion Criteria:

* Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
* Patients with primary brain tumors or leptomeningeal metastases are excluded.
* Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
* Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.

Note: there are additional exclusion criteria that may apply

Primary outcomes:
measure: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
timeFrame: Assessed at 16 weeks of treatment
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham Comprehensive Cancer Center
state: Alabama
city: Phoenix
country: United States
facility: Cancer Treatment Centers of America-Phoenix
state: Arizona
city: Auburn
country: United States
facility: Sutter Auburn
state: California
city: Berkeley
country: United States
facility: Sutter Alta Bates
state: California
city: Los Angeles
country: United States
facility: The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
state: California
city: Oakland
country: United States
facility: Kaiser Permanente - Oakland Medical Center
state: California
city: Palo Alto
country: United States
facility: Sutter Palo Alto Medical Foundation: Palo Alto
state: California
city: Roseville
country: United States
facility: Kaiser Permanente - Roseville Medical Center
state: California
city: Roseville
country: United States
facility: Sutter Roseville
state: California
city: Sacramento
country: United States
facility: Kaiser Permanente - Sacramento Medical Center
state: California
city: Sacramento
country: United States
facility: Sutter Sacramento
state: California
city: San Francisco
country: United States
facility: Kaiser Permanente - South San Francisco Medical Center
state: California
city: San Francisco
country: United States
facility: California Pacific Medical Center Research Institute
state: California
city: San Francisco
country: United States
facility: Kaiser Permanente - San Francisco Medical Center
state: California
city: San Francisco
country: United States
facility: Sutter Cancer Research Consortium
state: California
city: San Jose
country: United States
facility: Kaiser Permanente - San Jose Medical Center
state: California
city: San Leandro
country: United States
facility: Kaiser Permanente - San Leandro Medical Center
state: California
city: Santa Clara
country: United States
facility: Kaiser Permanente - Santa Clara Medical Center
state: California
city: Santa Cruz
country: United States
facility: Sutter Palo Alto Medical Foundation: Santa Cruz
state: California
city: Santa Cruz
country: United States
facility: Sutter Palo Alto Medical Foundation: Fremont
state: California
city: Sunnyvale
country: United States
facility: Sutter Palo Alto Medical Foundation: Sunnyvale
state: California
city: Vallejo
country: United States
facility: Kaiser Permanente - Vallejo Medical Center
state: California
city: Walnut Creek
country: United States
facility: Kaiser Permanente - Walnut Creek Medical Center
state: California
city: Bridgeport
country: United States
facility: Saint Vincent's Medical Center (SVMC)
state: Connecticut
city: Hartford
country: United States
facility: Hartford Hospital
state: Connecticut
city: Meriden
country: United States
facility: Midstate Medical Center (MSMC)
state: Connecticut
city: New Britain
country: United States
facility: The Hospital of Central Connecticut (HOCC) Cancer Center
state: Connecticut
city: Norwich
country: United States
facility: William W. Backus Hospital
state: Connecticut
city: Torrington
country: United States
facility: Charlotte Hungerford
state: Connecticut
city: Willimantic
country: United States
facility: Windham Hospital (WH)
state: Connecticut
city: Altamonte Springs
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Bonita Springs
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Bradenton
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Brandon
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Cape Coral
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Clearwater
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Fort Lauderdale
country: United States
facility: Holy Cross Hospital
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Gainesville
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Gainesville
country: United States
facility: University of Florida Health
state: Florida
city: Largo
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Lecanto
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Miami
country: United States
facility: University of Miami Sylvester Comprehensive Cancer Center
state: Florida
city: Naples
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Ocala
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Orange City
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Orlando
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Port Charlotte
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Saint Petersburg
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Sarasota
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Sarasota
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Tampa
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Tavares
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: The Villages
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Trinity
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Venice
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Venice
country: United States
facility: Florida Cancer Specialists South / Sarah Cannon Research Institute
state: Florida
city: Winter Park
country: United States
facility: Florida Cancer Specialists North / Sarah Cannon Research Institute
state: Florida
city: Atlanta
country: United States
facility: Cancer Treatment Centers of America - Atlanta
state: Georgia
city: Atlanta
country: United States
facility: Emory University Winship Cancer Institute
state: Georgia
city: Savannah
country: United States
facility: Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
state: Georgia
city: Savannah
country: United States
facility: Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
state: Georgia
city: Savannah
country: United States
facility: Lewis Cancer & Research Pavilion
state: Georgia
city: Savannah
country: United States
facility: Summit Cancer Care
state: Georgia
city: 'Ewa Beach
country: United States
facility: The Queen's Medical Center - West Oahu
state: Hawaii
city: Honolulu
country: United States
facility: The Queen's Medical Center - POB I
state: Hawaii
city: Honolulu
country: United States
facility: The Queen's Medical Center - Punchbowl
state: Hawaii
city: Honolulu
country: United States
facility: The Queen's Medical Center - Kuakini
state: Hawaii
city: Chicago
country: United States
facility: Cancer Treatment Centers of America-Chicago
state: Illinois
city: Indianapolis
country: United States
facility: Community Health Network (The University of Texas MD Anderson Cancer Center)
state: Indiana
city: Augusta
country: United States
facility: Harold Alfond Center for Cancer Care
state: Maine
city: Augusta
country: United States
facility: Jackson Laboratory - Maine Cancer Genomics Initiative
state: Maine
city: Belfast
country: United States
facility: Waldo County General Hospital
state: Maine
city: Biddeford
country: United States
facility: SMHC Cancer Care and Blood Disorders -Biddeford
state: Maine
city: Brewer
country: United States
facility: Northern Light Cancer Care
state: Maine
city: Brewer
country: United States
facility: Raish Peavey Haskell Children's Cancer and Treatment Center
state: Maine
city: Brunswick
country: United States
facility: MaineHealth Cancer Care -Brunswick
state: Maine
city: Kennebunk
country: United States
facility: New England Cancer Specialist
state: Maine
city: Kittery
country: United States
facility: York Hopsital Oncology & Infusion Care in Kittery
state: Maine
city: Norway
country: United States
facility: Stephens Memorial Hospital
state: Maine
city: Rockport
country: United States
facility: Penobscot Bay Medical Center
state: Maine
city: Sanford
country: United States
facility: SMHC Cancer Care and Blood Disorders -Sandford
state: Maine
city: Scarborough
country: United States
facility: Maine Children's Cancer Program
state: Maine
city: Scarborough
country: United States
facility: Maine Medical Partner's Women's Health
state: Maine
city: Scarborough
country: United States
facility: New England Cancer Specialist
state: Maine
city: South Portland
country: United States
facility: MaineHealth Cancer Care -South Portland
state: Maine
city: Topsham
country: United States
facility: New England Cancer Specialist
state: Maine
city: Wells
country: United States
facility: York Hospital Oncology & Infusion Care in Wells
state: Maine
city: York
country: United States
facility: York Hospital Oncology & Infusion Care in York
state: Maine
city: Ann Arbor
country: United States
facility: Trinity Health Ann Arbor Hospital
state: Michigan
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: Detroit
country: United States
facility: Ascension St. John Hospital
state: Michigan
city: Grand Blanc
country: United States
facility: Genesys Hurley Cancer Institute
state: Michigan
city: Grand Rapids
country: United States
facility: Cancer Research Consortium of West Michigan
state: Michigan
city: Lansing
country: United States
facility: Sparrow Hospital
state: Michigan
city: Livonia
country: United States
facility: Trinity Health Livonia Hospital
state: Michigan
city: Pontiac
country: United States
facility: Trinity Health Oakland Hospital
state: Michigan
city: Saginaw
country: United States
facility: Ascension St. Mary's Hospital
state: Michigan
city: Traverse City
country: United States
facility: Michigan Cancer Research Consortium
state: Michigan
city: Warren
country: United States
facility: St. John Macomb Oakland Hospital
state: Michigan
city: Omaha
country: United States
facility: University of Nebraska Medical Center
state: Nebraska
city: Concord
country: United States
facility: NH Oncology - Hematology, PA
state: New Hampshire
city: Manchester
country: United States
facility: Solinsky Center for Cancer Care
state: New Hampshire
city: Portsmouth
country: United States
facility: New England Cancer Specialist
state: New Hampshire
city: Albuquerque
country: United States
facility: Lovelace Medical Center - Saint Joseph Square
state: New Mexico
city: Albuquerque
country: United States
facility: Presbyterian Kaseman Hospital
state: New Mexico
city: Albuquerque
country: United States
facility: The University of New Mexico Comprehensive Cancer Center
state: New Mexico
city: Las Cruces
country: United States
facility: Memorial Medical Center
state: New Mexico
city: Rio Rancho
country: United States
facility: Presbyterian Rust Medical Center
state: New Mexico
city: Lake Success
country: United States
facility: Northwell Health Monter Cancer Center
state: New York
city: Mount Kisco
country: United States
facility: Northern Westchester Hospital
state: New York
city: New Hyde Park
country: United States
facility: Cohen Children's Medical Center
state: New York
city: New York
country: United States
facility: Herbert Irving Comprehensive Cancer Center
state: New York
city: New York
country: United States
facility: Manhattan Eye, Ear, and Throat Hospital
state: New York
city: New York
country: United States
facility: Staten Island University Hospital
state: New York
city: Rego Park
country: United States
facility: Queens Cancer Center
state: New York
city: Sleepy Hollow
country: United States
facility: Phelps Hospital
state: New York
city: Chapel Hill
country: United States
facility: Lineberger Comprehensive Cancer Center
state: North Carolina
city: Charlotte
country: United States
facility: Atrium Health's Levine Cancer Institute
state: North Carolina
city: Bismarck
country: United States
facility: Sanford Health- Bismarck
state: North Dakota
city: Fargo
country: United States
facility: Sanford Health- Fargo
state: North Dakota
city: Cincinnati
country: United States
facility: University of Cincinnati Medical Center
state: Ohio
city: Kettering
country: United States
facility: Kettering Health
state: Ohio
city: West Chester
country: United States
facility: West Chester Hospital
state: Ohio
city: Portland
country: United States
facility: Providence Health & Services
state: Oregon
city: Allentown
country: United States
facility: Lehigh Valley Health Network
state: Pennsylvania
city: Bethlehem
country: United States
facility: Lehigh Valley Hospital- Muhlenberg
state: Pennsylvania
city: East Stroudsburg
country: United States
facility: Pocono Medical Center
state: Pennsylvania
city: Hazleton
country: United States
facility: Lehigh Valley Hospital-Hazleton
state: Pennsylvania
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Bluffton
country: United States
facility: SC Cancer Specialists at St. Joseph's/Candler Bluffton
state: South Carolina
city: Bluffton
country: United States
facility: St. Joseph's/Candler Smith
state: South Carolina
city: Bluffton
country: United States
facility: Summit Cancer Care at St. Josph's/Candler Bluffton
state: South Carolina
city: Hilton Head Island
country: United States
facility: South Carolina Cancer Specialists
state: South Carolina
city: Sioux Falls
country: United States
facility: Sanford Cancer Center Oncology Clinic and Pharmacy
state: South Dakota
city: Nashville
country: United States
facility: Tennessee Oncology - Nashville / Sarah Cannon Research Institute
state: Tennessee
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
city: Cedar City
country: United States
facility: Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
state: Utah
city: Saint George
country: United States
facility: Dixie Regional Medical Center-River Road Campus
state: Utah
city: Salt Lake City
country: United States
facility: Intermountain Healthcare
state: Utah
city: Fairfax
country: United States
facility: Inova Schar Cancer Institute
state: Virginia
city: Seattle
country: United States
facility: Swedish Cancer Institute
state: Washington
city: Burlington
country: United States
facility: Aurora Cancer Care - Burlington
state: Wisconsin
city: Germantown
country: United States
facility: Aurora Health Care - Germantown Health Center
state: Wisconsin
city: Grafton
country: United States
facility: Aurora Cancer Care - Grafton
state: Wisconsin
city: Green Bay
country: United States
facility: Aurora BayCare Medical Center
state: Wisconsin
city: Kenosha
country: United States
facility: Aurora Cancer Care - Kenosha South
state: Wisconsin
city: Marinette
country: United States
facility: Aurora Bay Area Medical Center
state: Wisconsin
city: Milwaukee
country: United States
facility: Aurora Cancer Care Milwaukee
state: Wisconsin
city: Milwaukee
country: United States
facility: Aurora St. Luke's Medical Center
state: Wisconsin
city: Milwaukee
country: United States
facility: Aurora Sinai Medical Center
state: Wisconsin
city: Milwaukee
country: United States
facility: Aurora West Allis Medical Center
state: Wisconsin
city: Oshkosh
country: United States
facility: Vince Lombardi Cancer Clinic - Oshkosh
state: Wisconsin
city: Racine
country: United States
facility: Aurora Cancer Care - Racine
state: Wisconsin
city: Sheboygan
country: United States
facility: Vince Lombardi Cancer Center
state: Wisconsin
city: Summit
country: United States
facility: Aurora Medical Center in Summit
state: Wisconsin
city: Two Rivers
country: United States
facility: Vince Lombardi Cancer Clinic - Two Rivers
state: Wisconsin
city: Wauwatosa
country: United States
facility: Aurora Cancer Care - Milwaukee West
state: Wisconsin
Study officials:
References:
citation: Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
citation: Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
citation: Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
citation: Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.